Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for ICI-Induced Pruritus in Solid Cancer
NCT06931119Phase 1Not yet recruiting
- Sponsor
- Rabin Medical Center
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of aprepitant in pruritus, sponsored by Rabin Medical Center. Primary endpoint: Response defined as 6 points reduction of pruritus intensity at 12 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
aprepitant
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT06931119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931119.